A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Summary

The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary objective is to determine the response to treatment (based on bone marrow and peripheral blood findings). A tertiary objective is to determine the impact of therapy on health-related quality of life (HRQOL) and patient-reported outcomes (PRO). A quaternary (scientific) objective is to determine the impact of treatment on both hematopoietic and stromal cell populations within the bone marrow of MDS patients.

Timeline

Start

2019-02-14

Primary completion

2022-04-01

Completion

2022-06-06

Drugs

Indications